Table 2.

Univariate Analysis of Potential Prognostic Determinants of Adverse Outcome

	HR (95% CI)	P Value
Clinical characteristics
Age (per year)	1.01 (0.99–1.04)	0.41
Male sex	1.24 (0.60–2.55)	0.57
Chronic HF	4.08 (1.25–13.29)	0.02
Acute lung edema	1.35 (0.65–2.79)	0.42
NYHA class at admission
II	1
III	0.65 (0.09–4.92)	0.68
IV	0.93 (0.12–6.94)	0.94
Ischemic heart disease	2.68 (1.34–5.33)	0.005
AF	0.53 (0.27–1.06)	0.07
Arterial HT	1.15 (0.58–2.28)	0.68
DM	1.62 (1.17–2.25)	0.004
COPD	0.72 (0.29–1.77)	0.47
Anemia	2.31 (1.20–4.43)	0.01
LVSD (vs preserved systolic function)	1.86 (0.72–4.82)	0.20
Medications in use
Aspirin	2.42 (1.27–4.62)	0.007
β‐Blocker	1.66 (0.87–3.16)	0.12
ACEI or ARB	2.17 (1.07–4.39)	0.032
Spironolactone	1.27 (0.50–3.27)	0.62
Statin	2.16 (1.13–4.15)	0.020
Laboratory parameters at discharge
CCl ≤30 mL/min	1.39 (0.61–3.18)	0.44
Tn I, per mg/L	0.94 (0.72–1.23)	0.66
BNP, per 100 pg/mL	1.06 (1.03–1.08)	<0.001
Sodium, per mEq/L	1.00 (0.93–1.08)	0.91
CRP >12.3 mg/L	2.46 (1.29–4.70)	0.006

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BNP, b‐type natriuretic peptide; CCl, creatinine clearance; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; DM, diabetes mellitus; HF, heart failure; HR, hazard ratio; HT, hypertension; LVSD, left ventricular systolic dysfunction; NYHA: New York Heart Association; Tn I, troponin I